News Lipocine Inc.

Equities

LPCN

US53630X2036

Delayed Nasdaq Other stock markets 12:26:41 2024-04-25 pm EDT			5-day change	1st Jan Change
4.59 ^USD	+3.38%		-15.62%	+64.52%

Apr. 12	Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial	MT
Apr. 11	Top Premarket Gainers	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial	Apr. 12	MT
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity	Apr. 12	AQ
Top Premarket Gainers	Apr. 11	MT
Lipocine Inc. Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity	Apr. 11	CI
Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis	Mar. 28	PR
Lipocine Inc. Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis	Mar. 28	CI
Lipocine Doses First Group in Pivotal Study of Potential Postpartum Depression Drug	Mar. 25	MT
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154	Mar. 25	PR
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154	Mar. 25	CI
Lipocine : Announces First Cohort Dosed in Pivotal Study of LPCN 1154 - Form 8-K	Mar. 25	PU
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023	Mar. 08	AQ
Lipocine : Announces Financial Results for the Full Year Ended December 31, 2023 - Form 8-K	Mar. 07	PU
Lipocine Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Lipocine to Present at 36th Annual Roth Conference	Mar. 06	PR
Lipocine : to Present at 36th Annual Roth Conference - Form 8-K	Mar. 06	PU
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154	Feb. 06	PR
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154	Feb. 06	CI
Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals	Feb. 02	PR
Lipocine and Verity Pharma Enter into License Agreement for TLANDO Franchise in the U.S. and Canada	Jan. 19	AQ
Lipocine Enters Licensing Deal With Verity Pharmaceuticals for TLANDO in US, Canada	Jan. 18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Lipocine Inc.

Equities

LPCN

US53630X2036

Summary

Filters